SCHEMBL5909313

SCHEMBL5909313

CCN1CCN(C(=O)c2cnccc2C(F)(F)F)CC1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 1/20 0.58
NAMPT P43490 1/20 0.48
TP53 P04637 6/20 0.46
MDM2 Q00987 6/20 0.46
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
FAAH O00519 1/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
SCD O00767 2/20 0.43
PIK3CA P42336 1/20 0.42
MTOR P42345 1/20 0.42
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5909096 0.86 RBP4 (0.57) RBP4NAMPTTP53MDM2PSEN1
SCHEMBL5909108 0.85 RBP4 (0.61) RBP4NAMPTTP53MDM2PSEN1
SCHEMBL7095639 0.84 RBP4 (0.65) RBP4NAMPTTP53MDM2PSEN1
SCHEMBL29944078 0.82 RBP4 (0.64) RBP4NAMPTTP53MDM2PSEN1
SCHEMBL2818661 0.82 RBP4 (0.58) RBP4NAMPTTP53MDM2PSEN1
Hydrochloric Acid SCHEMBL2819736 0.81 RBP4 (0.57) RBP4NAMPTTP53MDM2PSEN1
SCHEMBL2818657 0.81 RBP4 (0.59) RBP4NAMPTTP53MDM2PSEN1
SCHEMBL14595381 0.80 KDM4E (0.44) MDM2POLB
SCHEMBL14595382 0.80 HSD11B1 (0.43) NPC1POLB
SCHEMBL5909231 0.79 RBP4 (0.63) RBP4TP53MDM2SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060030557-A1 Substituted pyridines having antiangiogenic activity HAVIV FORTUNA 2006-02-09 US disclosed
US-20040014744-A1 Substituted pyridines having antiangiogenic activity ABBOTT LABORATORIES 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014744-A1 Substituted pyridines having antiangiogenic activity FLT1, FLT4, KDR RBP4 1405/4885NAMPT 226/4885TP53 593/4885
US-20060030557-A1 Substituted pyridines having antiangiogenic activity FLT4, KDR, FLT1 RBP4 1151/4885NAMPT 140/4885TP53 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.